Gunther Birznieks - Mar 2, 2023 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Signature
/s/ Gunther Birznieks
Stock symbol
VNDA
Transactions as of
Mar 2, 2023
Transactions value $
-$104,584
Form type
4
Date filed
3/6/2023, 05:24 PM
Previous filing
Feb 21, 2023
Next filing
Feb 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VNDA Common Stock Sale -$52.8K -8.51K -3.82% $6.20 214K Mar 2, 2023 Direct F1, F2
transaction VNDA Common Stock Sale -$51.8K -8.27K -3.86% $6.26 206K Mar 3, 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.1901 to $6.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.2301 to $6.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.